Siegfried Holding Ag · SIX:SFZN
Siegfried — H1 2021 Earnings Presentation
23 slides from Siegfried's earnings presentation, Aug 19, 2021
Slide 1: Further on track: Siegfried increases sales and earnings in H1 2021
Further on track: Siegfried increases sales and earnings in H1 2021 Media & Analyst Virtual Conference Zofingen – 19 August 2021
Slide 2: Safe harbor statement
Safe harbor statement This document is solely for use in connection with the presentation held by Siegfried Holding AG. It is furnished to you for your information and you may not reproduce it or redistribute to any other person. No representation or warranty, express or implied, is made to, and no
Slide 3: Agenda
Agenda Status & Outlook Facts & Figures Strategy Q&A Media & Analyst Virtual Conference – 19 August 2021 3
Slide 4: Further on track in H1 2021: Siegfried delivers growth on all levels
Further on track in H1 2021: Siegfried delivers growth on all levels while consistently implementing its strategy and mastering short-term challenges › Siegfried grows on all levels – despite a temporary set-back by a cyber attack: Net sales of CHF 466.9m (+20.2% in CHF, +19.4% in LC) Core EBITD
Slide 5: Agenda
Agenda Status & Outlook Facts & Figures Strategy Q&A Media & Analyst Virtual Conference – 19 August 2021 5
Slide 6: Siegfried shows much higher net sales in H1 2021
Siegfried shows much higher net sales in H1 2021 – Acquisition in DP, existing business hindered only temporarily by a cyber attack CHF million H1 2021 H1 2020 Change Drug Substances 274.5 290.2 -5.4% Drug Products 192.3 97.9 +96.4% Total 466.9 388.1 +20.3% (+19.4% in LC1) Net sales split › Most of
Slide 7: Reconciliation of Swiss GAAP FER EBITDA to Core Net Profit
Reconciliation of Swiss GAAP FER EBITDA to Core Net Profit: Small and recurring adjustments CHF million Core adjustments 2.7 80.5 40.1 Swiss GAAP FER figures 77.3 0.5 40.4 1.0 -0.5 32.6 -8.9 0.6 EBITDA Current Integration Core Depreciation Core Financial Current Taxes Reversal Core Swiss net interes
Slide 8: Consolidated Core Income Statement: Jump in Sales and profits
Consolidated Core Income Statement: Jump in Sales and profits CHF million H1 2021 H1 2020 Core results Net sales 466.9 388.1 Cost of goods sold -374.6 -315.9 Gross profit 92.3 72.2 Marketing and sales costs -7.5 -7.3 Research and development costs -19.3 -14.4 Core administration and general overhead
Slide 9: Significant improvement in operating cash flow and free cash flow
Significant improvement in operating cash flow and free cash flow – laying the foundations for investments into future growth CHF million H1 2021 H1 2020 Operating cash flow before changes in NWC 85.7 65.5 Change in NWC 11.2 -20.5 Operating cash flow 96.9 45.0 Purchase of PPE and intangibles (net) -
Slide 10: Profit levels and margins: Improved on all levels
Profit levels and margins: Improved on all levels, despite short-term challenges CHF million 100 92.3 80.5 75 72.2 58.1 50 40.4 31.3 32.6 25 21.5 19.8% 18.6% 17.3% 15.0% 8.6% 8.1% 7.0% 5.5% 0 Gross profit Core EBITDA Core EBIT Core net profit H1 2021 % % Margin in % of net sales H1 2020 Business mod
Slide 11: Capital allocation framework
Capital allocation framework: Strong cash generation and strong balance sheet support our strategy EVOLVE 1 2 3 4 Re-invest in organic M&A – Deleverage and growth – Pay-out policy in line with strategy optimize funding cost in line with strategy › Maintenance CapEx › Successful placement › Disciplin
Slide 12: Agenda
Agenda Status & Outlook Facts & Figures Strategy Q&A Media & Analyst Virtual Conference – 19 August 2021 12
Slide 13: Siegfried's strategy EVOLVE on track
Siegfried’s strategy EVOLVE on track: Drive organic and external growth by executing a set of independent strategic initiatives › Strengthening capabilities and technology base in small molecule Investments in manufacturing technology base › Organic expansion into large molecules: Aseptic fill & fin
Slide 14: Investments in technology base and existing network
Investments in technology base and existing network: Supporting future growth and enhancing global competitiveness DS Network DP Network Corporate Network The role model: Efficient distribution of capabilities along all sites to Catching up: With the two new sites in Barcelona, Siegfried’s drug best
Slide 15: New Development Center of Excellence in Barcelona
New Development Center of Excellence in Barcelona to support new business development for local and global DP network Investment highlights and status: › Establishment Development Center of Excellence (CoE) in Barcelona leveraging existing infrastructure and talent › Fast-track execution: New labora
Slide 16: Investments into additional capacity and differentiating technologies
Investments into additional capacity and differentiating technologies to serve customer demand and build out strategic partnerships › Cooperation and supply agreement for large-scale aseptic mRNA COVID filling, finishing and packaging of BNT162b2 (Comirnaty®) for vaccine filling in BioNTech signed i
Slide 17: Siegfried's commitment to sustainability
Siegfried’s commitment to sustainability: Deeply embedded in our DNA and acknowledged by leading reporting standards › “Sustainability” is one of our five core values and an integral part of our corporate governance in a broad sense: “Siegfried is here not only for tomorrow, but for the next 150 yea
Slide 18: The next step: Carbon footprint reduction target until 2030
The next step: Carbon footprint reduction target until 2030 and commitment beyond 1 Reduction of CO2-eq by 50% until 2030 Carbon Footprint Targets CO2 equivalents1 / CHFm Sales (indexed = 100) Specific reduction target: 100 › Reduce Siegfried’s carbon footprint by 50% 1 until 2030 compared to 2020 (
Slide 19: Siegfried's ambition: Consistently deliver profitable growth
Siegfried’s ambition: Consistently deliver profitable growth and invest in optimization and expansion of the global network Siegfried 2020 Strategy EVOLVE Siegfried Vision Accelerated growth through M&A › Value accretive acquisitions in core Further evolve as a global areas › Acquisitive entry to ne
Slide 20: Agenda
Agenda Status & Outlook Facts & Figures Strategy Q&A Media & Analyst Virtual Conference – 19 August 2021 20
Slide 21: Questions & Answers
Further on track: Siegfried increases sales and earnings in H1 2021 Questions & Answers
Slide 22: Financial reporting on full year 2021
Financial reporting on full year 2021 23 February 2022 in Zurich 10.30 a.m. Media representatives 2.00 p.m. Financial analysts Media & Analyst Virtual Conference – 19 August 2021 22
Slide 23: Siegfried
Siegfried | inden » ~ FF. Evionnaz Saint-Vulb. Pennsville 7 Barbera Irvine Ps EI Masni aa expect more